Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables
15 March 2022
| COVID-19: Vaccines
Overview
These are the annexes to WHO interim recommendations on the use of CoronaVac vaccine developed by Sinovac. Annexes 1–6 contain tables that summarize the grading of recommendations, assessment, development and evaluations (GRADE). Annexes 7–9 contain the SAGE evidence-to-recommendation framework tables (ETR tables).
GRADE and ETR tables are updated as recommendations are updated.
For translations of this document in other languages, click here.
This document has been updated: version 15 March 2022.
Related documents:
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
Archived versions:
- Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables. Version 24 May 2021
- Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: Grading of evidence, Evidence to recommendation tables. Version 21 October 2021.
WHO Team
Agenda, Policy & Strategy (APS),
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ)
Number of pages
36
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/Sinovac-CoronaVac/annexes/2021.2
Copyright
